Recent developments include capital raises through private placements and public offerings, extension of rhNELL-1 shelf life, and regulatory compliance actions related to Nasdaq listing standards.

• Bone Biologics extended the shelf life of its rhNELL-1 protein to 32 months, enhancing study readiness [N1].
• The company priced up to $9 million private placement of shares and warrants in July 2026 [N2].
• Bone Biologics priced a $5 million public offering with warrants at $4 per share in June 2025 [N3].
• The company initiated a 1-for-6 reverse stock split effective June 10, 2025 [N5].
• Bone Biologics reported quarterly earnings results in May 2025 [N6].
• The company announced pricing of a $2 million public offering in March 2024 [N7].
• Bone Biologics was authorized for a 1-for-8 reverse stock split in December 2023 [N8].

Bone Biologics has demonstrated progress through key development milestones including successful manufacturing, animal studies, and initiation of a pilot clinical trial. The extension of rhNELL-1 shelf life to 32 months enhances study readiness and potential commercial viability. The company’s capital raises provide funding to support ongoing clinical and regulatory activities. The targeted mechanism of NELL-1 offers potential advantages in safety and efficacy over existing bone regeneration products, addressing unmet clinical needs in spinal fusion and other orthopedic indications. The exclusive license agreement with UCLA TDG and a growing scientific publication record support the technology’s credibility.

Bone Biologics faces significant risks including the uncertainty of regulatory approval for its Class III medical device, potential delays or failures in clinical trials, and the need for continued capital to fund development. The company’s stock price has triggered Nasdaq non-compliance notifications, risking delisting and reduced liquidity. Competition from larger, better-resourced orthopedic companies may limit market penetration. The company’s financial losses and limited revenue visibility add to execution risk. Reverse stock splits may not sustain compliance or investor interest, and the company’s ability to commercialize its technology remains unproven.

Bone Biologics’ moat is based on its proprietary recombinant human protein NELL-1 technology licensed exclusively from UCLA Technology Development Group, supported by extensive preclinical validation and a growing body of peer-reviewed research. The targeted mechanism of action of NELL-1 combined with FDA-cleared DBM provides a differentiated approach to bone regeneration with potential safety and efficacy advantages. The company’s exclusive worldwide license rights and patent portfolio provide intellectual property protection. However, the company operates in a competitive and rapidly evolving orthopedic market with established large players possessing greater resources. Regulatory approval requirements and clinical development risks also present barriers to entry for competitors but pose execution challenges for Bone Biologics.

• Regulatory Approval Risk: Bone Biologics’ lead product NB1 requires FDA pre-market approval as a Class III medical device, involving extensive clinical trials and regulatory review with no assurance of approval.
• Clinical Development Risk: The company’s clinical-stage status means ongoing trials may encounter delays, adverse events, or fail to demonstrate safety and efficacy endpoints.
• Financial and Liquidity Risk: Bone Biologics reported net losses and relies on capital raises to fund operations; failure to secure adequate funding could impair development progress.
• Nasdaq Listing Compliance Risk: The company has received Nasdaq notifications for non-compliance with minimum bid price rules and market value requirements, risking delisting and reduced stock liquidity.
• Competitive Risk: Bone Biologics operates in a competitive orthopedic market with large established companies that have greater resources and market presence.

• Bone Biologics Corp is a clinical-stage medical device company focused on bone regeneration in spinal fusion using recombinant human protein NELL-1 combined with demineralized bone matrix (DBM).
• NELL-1/DBM is an osteopromotive recombinant protein providing targeted control over bone regeneration, licensed exclusively from UCLA Technology Development Group.
• The company has completed key milestones including manufacturing pilot runs, animal model validations, pivotal animal studies, and initiated a first-in-man pilot clinical study in Australia for lumbar spinal fusion.
• The pilot clinical study evaluates safety and effectiveness of NB1 device in up to 30 adult subjects undergoing transforaminal lumbar interbody fusion for degenerative disc disease.
• NELL-1 technology has potential applications beyond spinal fusion including trauma, osteoporosis, and other orthopedic procedures.
• The company’s lead product candidate NB1 is a convenience kit combining purified NELL-1 protein with FDA-cleared DBM putty from MTF Biologics.
• NELL-1/DBM Fusion Device is regulated as a Class III medical device requiring FDA pre-market approval (PMA).
• Bone Biologics has an exclusive license agreement with UCLA TDG with milestone and royalty payment obligations.
• The company has conducted extensive preclinical research with over 80 publications, including pivotal sheep studies showing increased fusion rates and safety profile.
• Financial snapshot as of 2026-09-30 shows cash and equivalents of $6.19 million, current assets of $6.43 million, current liabilities of $0.48 million, resulting in a strong current ratio of 13.38 and cash ratio of 12.87.
• Net income for the quarter ending 2026-09-30 was a loss of $617,651 with basic and diluted EPS of -$0.17.
• Bone Biologics has conducted multiple capital raises including a $9 million private placement in July 2026 and a $5 million public offering in June 2025.
• The company implemented a 1-for-6 reverse stock split effective June 10, 2025, and was authorized for a 1-for-8 reverse stock split in December 2023.
• Bone Biologics received Nasdaq notification in September 2026 for non-compliance with the minimum bid price rule and is considering a reverse stock split to regain compliance.
• Risks include regulatory approval uncertainties, competitive pressures from larger orthopedic companies, and potential Nasdaq delisting risks due to stock price and market value deficiencies.